Plus Therapeutics at the NYSE with IPO Edge

Plus Therapeutics' President and CEO Marc Hedrick M.D. on the floor of the New York Stock Exchange speaking with IPO Edge Editor-in-Chief John Jannarone about the company's novel targeted radio-therapeutics treatment for central nervous system cancer using the latest technology, its future potential to treat any form of cancer in the brain and the spinal cord at any stage, among other topics.
#nasdaq #pstv #braincancer